News

NeoProgen, led by former Harpoon Medical CEO, raises $1.5M from Maryland investors

Oct. 17, 2019

NeoProgen, a Baltimore-based company led by medtech entrepreneur Bill Niland, raised $1.5 million in seed funding as it develops a cell therapy for patients following a heart attack.

NeoProgen, led by former Harpoon Medical CEO, raises $1.5M from Maryland investors

Oct. 17, 2019

NeoProgen, a Baltimore-based company led by medtech entrepreneur Bill Niland, raised $1.5 million in seed funding as it develops a cell therapy for patients following a heart attack.

NeoProgen, led by former Harpoon Medical CEO, raises $1.5M from Maryland investors

Oct. 17, 2019

NeoProgen, a Baltimore-based company led by medtech entrepreneur Bill Niland, raised $1.5 million in seed funding as it develops a cell therapy for patients following a heart attack.

NeoProgen Completes $1.5M Seed Financing With $245K Investment From USM Maryland Momentum Fund

October 16, 2019

NeoProgen, Inc., a preclinical stage therapeutics company located in Baltimore, has received a $245,000 investment from the University System of Maryland (USM) Maryland Momentum Fund to complete the company’s $1.5M seed funding round, which also includes participation from UMB, TEDCO (Maryland Venture Partners, L.P.) and UM Ventures.

Maryland Stem Cell Research Commission Announces $1,351,400 Million in Stem Cell Program Awards

September 10, 2019

The MSCRF awards of the 2020 fiscal year include:

  • 3 Commercialization: These awards assist with the creation of start-up companies or new technologies developed in Maryland-based companies. Totaling $892,080, the commercialization award recipients are Brian Pollok of Propagenix, Inc., Jamie Niland of NeoProgen, Inc., and Ines Silva of Reprocell, USA. 

Veteran medical device firm CEO aims to build three companies at once

Jun 27, 2019

Bill Niland has led multiple medical device companies throughout his career, and was the CEO behind the $250 million sale of Baltimore's Harpoon Medical in 2017. Now, he is working to build three more device companies here, with hopes to lead all of them through similar exits.